Genetic evolution of pancreatic cancer: Lessons learnt from the pancreatic cancer genome sequencing project

Gut

Volumn 61, Issue 7, 2012, Pages 1085-1094

  Iacobuzio Donahue, Christine A ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; MUCIN; TELOMERASE;

ACINAR CELL; ACVR1B GENE; CANCER DIAGNOSIS; CANCER GENETICS; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CARCINOGENESIS; CDKN2A GENE; CELL POPULATION; CLONAL EVOLUTION; CYSTADENOMA; EARLY DIAGNOSIS; EXOME; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GENE AMPLIFICATION; GENE DELETION; GENE FUNCTION; GENE INACTIVATION; GENE MAPPING; GENE MUTATION; GENE SEQUENCE; GENETIC ANALYSIS; HUMAN; HUMAN GENOME; INTRADUCTAL PAPILLARY MUCINOUS TUMOR; KRAS2 GENE; M PHASE CELL CYCLE CHECKPOINT; MOLECULAR EVOLUTION; MUTATIONAL ANALYSIS; ONCOGENE; PANCREAS ADENOCARCINOMA; PANCREAS ADENOMA; PANCREAS CANCER; PANCREAS DUCT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; REVIEW; SIGNAL TRANSDUCTION; SMAD4 GENE; STEM CELL; TELOMERE HOMEOSTASIS; TGFBR1 GENE; TGFBR2 GENE; TP53 GENE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

CARCINOMA, PANCREATIC DUCTAL; CELL TRANSFORMATION, NEOPLASTIC; CLONAL EVOLUTION; DNA MUTATIONAL ANALYSIS; EVOLUTION, MOLECULAR; GENOME, HUMAN; HUMANS; MUTATION; PANCREAS; PANCREATIC NEOPLASMS; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84861574101     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.236026     Document Type: Review

References (93)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J clin 2010;60:277-300.
2. Malvezzi M, Arfe A, Bertuccio P, et al. European cancer mortality predictions for the year 2011. Ann Oncol 2011;22:947-56.
3. Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol 2008;3:157-88. (Pubitemid 351488279)
4. Moskaluk CA, Hruban RH, Kern SE. p16 and K-ras gene mutations in the intraductal precursors of human pancreatic adenocarcinoma. Cancer Res 1997;57:2140-3. (Pubitemid 27247028)
5. Wilentz RE, Iacobuzio-Donahue CA, Argani P, et al. Loss of expression of Dpc4 in pancreatic intraepithelial neoplasia: evidence that DPC4 inactivation occurs late in neoplastic progression. Cancer Res 2000;60:2002-6. (Pubitemid 30207663)
6. Goggins M, Hruban RH, Kern SE. BRCA2 is inactivated late in the development of pancreatic intraepithelial neoplasia: evidence and implications. Am J Pathol 2000;156:1767-71. (Pubitemid 30646713)
7. Klein AP, Brune KA, Petersen GM, et al. Prospective risk of pancreatic cancer in familial pancreatic cancer kindreds. Cancer Res 2004;64:2634-8. (Pubitemid 38523922)
8. Jones S, Hruban RH, Kamiyama M, et al. Exomic sequencing identifies PALB2 as a pancreatic cancer susceptibility gene. Science 2009;324:217.
9. Hahn SA, Greenhalf B, Ellis I, et al. BRCA2 germline mutations in familial pancreatic carcinoma. J Natl Cancer Inst 2003;95:214-21. (Pubitemid 36240634)
10. Rogers CD, Couch FJ, Brune K, et al. Genetics of the FANCA gene in familial pancreatic cancer. J Med Genet 2004;41:e126.
11. Rogers CD, van der Heijden MS, Brune K, et al. The genetics of FANCC and FANCG in familial pancreatic cancer. Cancer Biol Ther 2004;3:167-9. (Pubitemid 41350898)
12. Bardeesy N, Aguirre AJ, Chu GC, et al. Both p16(Ink4a) and the p19(Arf)-p53 pathway constrain progression of pancreatic adenocarcinoma in the mouse. Proc Natl Acad Sci U S A 2006;103:5947-52.
13. Hingorani SR, Wang L, Multani AS, et al. Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 2005;7:469-83. (Pubitemid 40719130)
14. Skoulidis F, Cassidy LD, Pisupati V, et al. Germline Brca2 heterozygosity promotes Kras(G12D)-driven carcinogenesis in a murine model of familial pancreatic cancer. Cancer Cell 2010;18:499-509.
15. McDermott U, Downing JR, Stratton MR. Genomics and the continuum of cancer care. N Engl J Med 2011;364:340-50.
16. Matthaei H, Schulick RD, Hruban RH, et al. Cystic precursors to invasive pancreatic cancer. Nat Rev Gastroenterol Hepatol 2011;8:141-50.
17. Hruban RH, Goggins M, Parsons J, et al. Progression model for pancreatic cancer. Clin Cancer Res 2000;6:2969-72. (Pubitemid 30637716)
18. Winter JM, Cameron JL, Campbell KA, et al. 1423 pancreaticoduodenectomies for pancreatic cancer: a singleinstitution experience. J Gastrointest Surg 2006;10:1199-210; discussion 210-11.
19. Gaujoux S, Brennan MF, Gonen M, et al. Cystic lesions of the pancreas: changes in the presentation and management of 1,424 patients at a single institution over a 15-year time period. J Am Coll Surg 2011;212:590e600; discussion 600-3.
20. Miyamoto Y, Maitra A, Ghosh B, et al. Notch mediates TGF alphainduced changes in epithelial differentiation during pancreatic tumorigenesis. Cancer Cell 2003;3:565-76. (Pubitemid 36808651)
21. Stanger BZ, Stiles B, Lauwers GY, et al. Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 2005;8:185-95. (Pubitemid 41317590)
22. Guerra C, Schuhmacher AJ, Canamero M, et al. Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. Cancer Cell 2007;11:291-302. (Pubitemid 46349841)
23. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res 2007;67:1030-7.
24. Hruban RH, Adsay NV, Albores-Saavedra J, et al. Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions. Am J Surg Pathol 2001;25:579-86. (Pubitemid 32423354)
25. Furukawa T, Kloppel G, Volkan Adsay N, et al. Classification of types of intraductal papillary-mucinous neoplasm of the pancreas: a consensus study. Virchows Arch 2005;447:794-9. (Pubitemid 41728866)
26. Martinez P, Blasco MA. Telomeric and extra-telomeric roles for telomerase and the telomere-binding proteins. Nat Rev 2011;11:161-76.
27. Campbell PJ, Yachida S, Mudie LJ, et al. The patterns and dynamics of genomic instability in metastatic pancreatic cancer. Nature 2010;467:1109-13.
28. van Heek NT, Meeker AK, Kern SE, et al. Telomere shortening is nearly universal in pancreatic intraepithelial neoplasia. Am J Pathol 2002;161:1541-7. (Pubitemid 35265514)
29. Seki K, Suda T, Aoyagi Y, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res 2001;7:1976-81. (Pubitemid 32994834)
30. Almoguera C, Shibata D, Forrester K, et al. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988;53:549-54.
31. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev 2007;7:295-308. (Pubitemid 46480970)
32. Caldas C, Hahn SA, da Costa LT, et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994;8:27-32. (Pubitemid 24274057)
33. Schutte M, Hruban RH, Geradts J, et al. Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res 1997;57:3126-30. (Pubitemid 27351723)
34. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006;127:265-75. (Pubitemid 44572384)
35. Redston MS, Caldas C, Seymour AB, et al. p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 1994;54:3025-33. (Pubitemid 24187791)
36. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
37. Raycroft L, Wu HY, Lozano G. Transcriptional activation by wildtype but not transforming mutants of the p53 anti-oncogene. Science 1990;249:1049-51.
38. Goh AM, Coffill CR, Lane DP. The role of mutant p53 in human cancer. J Pathol 2011;223:116-26.
39. DiGiuseppe JA, Redston MS, Yeo CJ, et al. p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. Am J Pathol 1995;147:884-8.
40. Hahn SA, Schutte M, Hoque AT, et al. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 1996;271:350-3.
41. Massague J. TGFbeta in Cancer. Cell 2008;134:215-30.
42. Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. Cancer Res 1998;58:5329-32. (Pubitemid 28551110)
43. Su GH, Bansal R, Murphy KM, et al. ACVR1B (ALK4, activin receptor type 1B) gene mutations in pancreatic carcinoma. Proc Natl Acad Sci U S A 2001;98:3254-7. (Pubitemid 32220832)
44. Su GH, Hilgers W, Shekher MC, et al. Alterations in pancreatic, biliary, and breast carcinomas support MKK4 as a genetically targeted tumor suppressor gene. Cancer Res 1998;58:2339-42. (Pubitemid 28252690)
45. Blackford A, Serrano OK, Wolfgang CL, et al. SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer. Clin Cancer Res 2009;15:4674-9.
46. Taylor JL, Szmulewitz RZ, Lotan T, et al. New paradigms for the function of JNKK1/MKK4 in controlling growth of disseminated cancer cells. Cancer Lett 2008;272:12-22.
47. Hruban RH, Canto MI, Goggins M, et al. Update on familial pancreatic cancer. Adv Surg 2010;44:293-311.
48. Su GH, Hruban RH, Bansal RK, et al. Germline and somatic mutations of the STK11/LKB1 Peutz-Jeghers gene in pancreatic and biliary cancers. Am J Pathol 1999;154:1835-40. (Pubitemid 29262866)
49. van der Heijden MS, Yeo CJ, Hruban RH, et al. Fanconi anemia gene mutations in young-onset pancreatic cancer. Cancer Res 2003;63:2585-8. (Pubitemid 36605199)
50. Jansen M, Ten Klooster JP, Offerhaus GJ, et al. LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism. Physiol Rev 2009;89:777-98.
51. Wang W. Emergence of a DNA-damage response network consisting of Fanconi anaemia and BRCA proteins. Nat Rev Genet 2007;8:735-48. (Pubitemid 47429206)
52. Goldstein AM, Chan M, Harland M, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res 2006;66:9818-28. (Pubitemid 44672032)
53. Whitcomb DC, Gorry MC, Preston RA, et al. Hereditary pancreatitis is caused by a mutation in the cationic trypsinogen gene. Nat Genet 1996;14:141-5. (Pubitemid 26338792)
54. Lowenfels AB, Maisonneuve P, DiMagno EP, et al. Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst 1997;89:442-6. (Pubitemid 27136736)
55. Shi C, Hruban RH, Klein AP. Familial pancreatic cancer. Arch Pathol Lab Med 2009;133:365-74.
56. Amundadottir L, Kraft P, Stolzenberg-Solomon RZ, et al. Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet 2009;41:986-90.
57. Petersen GM, Amundadottir L, Fuchs CS, et al. A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet 2010;42:224-8.
58. Eberle MA, Pfutzer R, Pogue-Geile KL, et al. A new susceptibility locus for autosomal dominant pancreatic cancer maps to chromosome 4q32-34. Am J Hum Genet 2002;70:1044-8. (Pubitemid 34259323)
59. Pogue-Geile KL, Chen R, Bronner MP, et al. Palladin mutation causes familial pancreatic cancer and suggests a new cancer mechanism. PLoS Med 2006;3:e516.
60. Klein AP, Borges M, Griffith M, et al. Absence of deleterious palladin mutations in patients with familial pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2009;18:1328-30.
61. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001;409:860-921. (Pubitemid 32165345)
62. Wang Z, Shen D, Parsons DW, et al. Mutational analysis of the tyrosine phosphatome in colorectal cancers. Science 2004;304:1164-6.
63. Parsons DW, Wang TL, Samuels Y, et al. Colorectal cancer: mutations in a signalling pathway. Nature 2005;436:792. (Pubitemid 41160630)
64. Bardelli A, Parsons DW, Silliman N, et al. Mutational analysis of the tyrosine kinome in colorectal cancers. Science 2003;300:949. (Pubitemid 36548874)
65. Sjoblom T, Jones S, Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science 2006;314:268-74. (Pubitemid 44571966)
66. Stephens PJ, McBride DJ, Lin ML, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature 2009;462:1005-10.
67. Jones S, Zhang X, Parsons DW, et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008;321:1801-6.
68. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008;321:1807-12.
69. Pleasance ED, Stephens PJ, O'Meara S, et al. A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 2010;463:184-90.
70. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011;469:539-42.
71. Jiao Y, Shi C, Edil BH, et al. DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science 2011;331:1199-203.
72. Rozenblum E, Schutte M, Goggins M, et al. Tumor-suppressive pathways in pancreatic carcinoma. Cancer Res 1997;57:1731-4. (Pubitemid 27199667)
73. Greenman C, Wooster R, Futreal PA, et al. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics 2006;173:2187-98. (Pubitemid 44285695)
74. Parmigiani G, Boca S, Lin J, et al. Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics 2009;93:17-21.
75. Balakrishnan A, Bleeker FE, Lamba S, et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma. Cancer Res 2007;67:3545-50. (Pubitemid 46762135)
76. Velculescu VE. Defining the blueprint of the cancer genome. Carcinogenesis 2008;29:1087-91. (Pubitemid 351958685)
77. Hidalgo M. Pancreatic cancer. N Engl J Med 2010;362:1605-17.
78. Embuscado EE, Laheru D, Ricci F, et al. Immortalizing the complexity of cancer metastasis: genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. Cancer Biol Ther 2005;4:548-54. (Pubitemid 41351229)
79. Jones S, Chen WD, Parmigiani G, et al. Comparative lesion sequencing provides insights into tumor evolution. Proc Natl Acad Sci U S A 2008;105:4283-8. (Pubitemid 351754372)
80. Navin N, Krasnitz A, Rodgers L, et al. Inferring tumor progression from genomic heterogeneity. Genome Res 2010;20:68-80.
81. Klein WM, Hruban RH, Klein-Szanto AJ, et al. Direct correlation between proliferative activity and dysplasia in pancreatic intraepithelial neoplasia (PanIN): additional evidence for a recently proposed model of progression. Mod Pathol 2002;15:441-7. (Pubitemid 34326953)
82. Salk JJ, Horwitz MS. Passenger mutations as a marker of clonal cell lineages in emerging neoplasia. Semin Cancer Biol 2010;20:294-303.
83. Stathis A, Moore MJ. Advanced pancreatic carcinoma: current treatment and future challenges. Nat Rev Clin Oncol 2010;7:163-72.
84. Yachida S, Jones S, Bozic I, et al. Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 2010;467:1114-17.
85. Amikura K, Kobari M, Matsuno S. The time of occurrence of liver metastasis in carcinoma of the pancreas. Int J Pancreatol 1995;17:139-46.
86. Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004;19:182-6. (Pubitemid 38253358)
87. Caldas C, Hahn SA, Hruban RH, et al. Detection of K-ras mutations in the stool of patients with pancreatic adenocarcinoma and pancreatic ductal hyperplasia. Cancer Res 1994;54:3568-73. (Pubitemid 24225985)
88. Wang Q, Chaerkady R, Wu J, et al. Mutant proteins as cancer-specific biomarkers. Proc Natl Acad Sci U S A 2011;108:2444-9.
89. Berg CD, Aberle DR. Computed tomography screening for lung cancer. JAMA 2007;298:513e14; author reply 515-16.
90. Philip AK, Lubner MG, Harms B. Computed tomographic colonography. Surg Clin North Am 2011;91:127-39.
91. Shi C, Chandrasekaran A, Thuluvath PJ, et al. Ultrasensitive detection of KRAS2 mutations in bile and serum from patients with biliary tract carcinoma using LigAmp technology. J Mol Diagn 2009;11:583-9.
92. Greenhalf W, Grocock C, Harcus M, et al. Screening of high-risk families for pancreatic cancer. Pancreatology 2009;9:215-22.
93. Iacobuzio-Donahue CA, Klimstra DS, Adsay NV, et al. Dpc-4 protein is expressed in virtually all human intraductal papillary mucinous neoplasms of the pancreas: comparison with conventional ductal adenocarcinomas. Am J Pathol 2000;157:755-61. (Pubitemid 32109368)